Skip to content

Ocular Therapeutix OCUL Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$608K

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's capital investments accrued but not yet paid?
Ocular Therapeutix (OCUL) reported capital investments accrued but not yet paid of $1.33M in Q1 2026.
How has Ocular Therapeutix's capital investments accrued but not yet paid changed year-over-year?
Ocular Therapeutix's capital investments accrued but not yet paid increased by 135.3% year-over-year, from $564K to $1.33M.